2024
Dietary EPA and DHA enrichment of a high fat diet during doxorubicin-based chemotherapy attenuated neuroinflammatory gene expression in the brain of C57bl/6 ovariectomized mice
Ormiston K, Melink Z, Andridge R, Lustberg M, DeVries A, Murphy K, Emmers K, Ziouzenkova O, Belury M, Orchard T. Dietary EPA and DHA enrichment of a high fat diet during doxorubicin-based chemotherapy attenuated neuroinflammatory gene expression in the brain of C57bl/6 ovariectomized mice. Brain Behavior And Immunity 2024, 123: 370-382. PMID: 39313165, DOI: 10.1016/j.bbi.2024.09.021.Peer-Reviewed Original ResearchHOMA-IRChemotherapy-related cognitive impairmentHigh-fatDietary eicosapentaenoic acidDocosahexaenoic acidBlood-brain barrier regulationDoxorubicin-based chemotherapyFemale C57BL/6 miceLF groupEicosapentaenoic acidBody fat lossLow-fat (LFHF dietNeuroinflammatory gene expressionLipid metabolismMultiple genesReduction of oxidative stressAlterations of glucoseFat (LFHigh-fat dietGene expressionOvariectomized miceC57BL/6 miceChemotherapy agentsBreast cancerLow Sucrose Diets Protect Long-Term Memory and EPA & DHA Enriched Diets Alter Insulin Resistance in a Mouse Model of Chemotherapy
Ormiston K, Fitzgerald J, Andridge R, Lustberg M, DeVries A, Orchard T. Low Sucrose Diets Protect Long-Term Memory and EPA & DHA Enriched Diets Alter Insulin Resistance in a Mouse Model of Chemotherapy. Nutrition Research 2024 DOI: 10.1016/j.nutres.2024.09.004.Peer-Reviewed Original ResearchLiver lipid contentMouse model of chemotherapyLipid contentBody weightLong-term memorySucrose dietLow-sucrose dietDocosahexaenoic acidInsulin resistanceChemotherapy-related cognitive impairmentMouse modelEffects of EPA+DHADoxorubicin-based chemotherapyFemale C57BL/6 miceImpact of chemotherapyAltered insulin resistanceNegatively impacts quality of lifeInsulin resistance scoreDietResistance scoreLower sucrose consumptionEPA+DHARandomized to 1Affective side effectsEicosapentaenoic acid + docosahexaenoic acidMadarosis among breast cancer survivors
Premji S, Ruddy K, Larson N, Loprinzi C, Dulmage B, Lustberg M, Couch F, Olson J, Cathcart-Rake E. Madarosis among breast cancer survivors. Clinical Breast Cancer 2024 DOI: 10.1016/j.clbc.2024.09.002.Peer-Reviewed Original ResearchBreast cancer survivorsMayo Clinic Breast Disease RegistryQuality of lifeCancer survivorsProportion of breast cancer survivorsLower mental health scoresCohort studyChemotherapy recipientsMental health scoresDiagnosis of breast cancerLongitudinal cohort studyCancer-directed therapyProportion of participantsHealth scoresConsenting participantsDistressing symptomsAge of survivorsDisease RegistryMedian age of survivorsEyelash lossSurvivorsBreast cancerParticipantsEyebrow lossBreastPerceptions of delayed alopecia among breast cancer survivors
Premji S, Ruddy K, Vierkant R, Larson N, Loprinzi C, Dulmage B, Lustberg M, Couch F, Olson J, Cathcart-Rake E. Perceptions of delayed alopecia among breast cancer survivors. Clinical Breast Cancer 2024 DOI: 10.1016/j.clbc.2024.09.008.Peer-Reviewed Original ResearchBreast cancer survivorsMayo Clinic Breast Disease RegistryCancer survivorsChemotherapy recipientsStage I-III breast cancerI-III breast cancerBreast cancer diagnosisPersistent bothersome symptomsRespondents' median ageBreast cancer treatmentMental healthDistressing symptomsDisease RegistryCancer diagnosisCohort studyHair lossSurvivorsBreast cancerBothersome symptomsBreastRespondentsSurvey 6 yearsParticipantsBotherCancer treatmentPatterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic
Kang L, Kadan-Lottick N, Rotatori J, Kujawski S, Messerschmidt E, Auerbach C, Balsamo L, Lustberg M, Ma X, Rodwin R. Patterns of Physical Therapy Referral and Subsequent Attendance Among Childhood Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy at a Regional Childhood Cancer Survivorship Clinic. Seminars In Oncology Nursing 2024, 40: 151716. PMID: 39164160, DOI: 10.1016/j.soncn.2024.151716.Peer-Reviewed Original ResearchChildhood cancer survivorsChemotherapy-induced peripheral neuropathyCharacteristics of survivorsPhysical therapyPercentage of adultsPT referralSurvivorship clinicCancer survivorsAttended PTPT attendanceNeighborhood characteristicsChemotherapy-induced peripheral neuropathy symptomsCancer survivorship clinicPhysical therapy referralsHigh school diplomaSurvivor educationCare coordinationOlder survivorsTherapy referralsImprove attendanceMedian percentageCancer diagnosisSchool diplomaPercentage of householdsAttendanceEffect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial
Melink Z, Lustberg M, Schnell P, Mezzanotte-Sharpe J, Orchard T. Effect of minocycline on changes in affective behaviors, cognitive function, and inflammation in breast cancer survivors undergoing chemotherapy: a pilot randomized controlled trial. Breast Cancer Research And Treatment 2024, 1-13. PMID: 39143391, DOI: 10.1007/s10549-024-07457-w.Peer-Reviewed Original ResearchState-Trait Anxiety InventoryCES-DRandomized controlled trialsBC survivorsCancer survivorsEpidemiologic Studies Depression ScaleEffects of minocyclineBreast cancer survivorsCES-D scoresCognitive functionStage I-III BCSelf-reported cognitionCohort of BC survivorsBreast cancerAffective behaviorBaseline to 6Depression ScaleSub-group analysisInflammatory markersPost-chemotherapyAnxiety InventoryInterleukin-8State-TraitBaseline scoresControlled trialsAdherence to a MIND Diet Pattern Is Associated With Better Cognitive Function and Less Peripheral Inflammation in Breast Cancer Survivors
Orchard T, Winschel T, Weinhold K, Melink Z, Aase D, Schnell P, Gorka S, Lustberg M, Williams N. Adherence to a MIND Diet Pattern Is Associated With Better Cognitive Function and Less Peripheral Inflammation in Breast Cancer Survivors. Current Developments In Nutrition 2024, 8: 103175. DOI: 10.1016/j.cdnut.2024.103175.Peer-Reviewed Original ResearchPartnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial
Worthen-Chaudhari L, Schnell P, Hackney M, Lustberg M. Partnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial. Frontiers In Psychology 2024, 15: 1383143. PMID: 38962217, PMCID: PMC11220256, DOI: 10.3389/fpsyg.2024.1383143.Peer-Reviewed Original ResearchTherapeutic physical activityHome exercisesPhysical activitySurvivors of breast cancerSurvivors of cancerDance-based interventionsPartner dancePatient-reported outcomesRandomized controlled trialsIntrinsic motivationRandomized-controlled studyIntrinsic Motivation InventorySecondary analysisExerciseHealthy agingSocial danceSelf-determination theorySensorimotor function deficitsControlled clinical trialsDanceBreast cancerInterventionExtrinsic motivationMotivation InventoryNeuropathy diagnosisThe survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapyReal‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageImpact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).
Taylor M, Reddy S, Ashok Kumar P, Hariri D, Sokol E, Sivakumar S, Quintanilha J, Pavlick D, Levy M, Ross J, Lustberg M. Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2024, 42: 1092-1092. DOI: 10.1200/jco.2024.42.16_suppl.1092.Peer-Reviewed Original ResearchTriple negative breast cancerComprehensive genomic profilingGenomic alterationsHER2 statusHER2 2Triple negative breast cancer groupGA frequencyReview of pathology specimensHER2 IHC expressionHER2-low statusHER2-low tumorsLack of clinical dataPD-L1 expressionTumor mutational burdenHER2 IHC scoreHER2 2+Negative breast cancerEvaluate genomic alterationsMann-Whitney U testPotential treatment optionStatistically significant differenceHER2 subgroupsPD-L1Immunotherapy biomarkersChi-square testEpisodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors.
Sukumar J, Lustberg M, Stein J, Schnell P, King J, Schimming D, Hatfield R, Quiroga D, Pariser A, Gatti-Mays M, Williams N, Cherian M, Stover D, Wesolowski R, Ramaswamy B, Tripathy D, Basen-Engquist K, Vaughn J, Sardesai S. Episodic future thinking: A behavioral intervention to promote weight loss in breast cancer survivors. Journal Of Clinical Oncology 2024, 42: e22541-e22541. DOI: 10.1200/jco.2024.42.16_suppl.e22541.Peer-Reviewed Original ResearchEpisodic future thinkingBehavioral interventionsBC survivorsCancer survivorsMaladaptive health behaviorsBaseline DDFuture-oriented eventsBreast cancer survivorsImpact cancer survivorsDecreased impulsivityBehavior change methodsFuture thinkingDD ratesLifestyle engagementBehavioral economic principlesImmediate gratificationDigital behavioral interventionsLifestyle counselingHealth behaviorsLifestyle interventionPromote weight lossLinear mixed effects modelsDigital healthNon-metastatic BCAverage adherenceNeurofilament light chains: A biomarker for vincristine-related neuropathy.
McNally G, Xu M, Voorhees T, Baiocchi R, Bond D, Epperla N, Maddocks K, Sawhala Y, Ramaswamy B, Lustberg M. Neurofilament light chains: A biomarker for vincristine-related neuropathy. Journal Of Clinical Oncology 2024, 42: 12114-12114. DOI: 10.1200/jco.2024.42.16_suppl.12114.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPatient-reported outcomesNF-L levelsPeripheral neuropathyTime point 3Cancer Institute Common Terminology Criteria for Adverse EventsNational Cancer Institute Common Terminology Criteria for Adverse EventsCommon Terminology Criteria for Adverse EventsAggressive non-Hodgkin's lymphomaSymptoms of chemotherapy-induced peripheral neuropathyDose-adjusted EPOCHNon-Hodgkin's lymphomaNF-LVincristine-induced neurotoxicityTime pointsLight chainClinician-reported outcome measuresNeurofilament light chainEuropean Organization for Research and TreatmentCycle fourLymphoma treatmentLong-term qualityBlood-based biomarkersChemotherapy typeAdverse eventsSurvivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations
Hart N, Nekhlyudov L, Smith T, Yee J, Fitch M, Crawford G, Koczwara B, Ashbury F, Lustberg M, Mollica M, Smith A, Jefford M, Chino F, Zon R, Agar M, Chan R. Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations. JCO Oncology Practice 2024, 20: 1160-1172. PMID: 38684036, DOI: 10.1200/op.23.00716.Peer-Reviewed Original ResearchQuality survivorship careSurvivorship carePractice recommendationsUnmet supportive care needsPalliative care frameworkSupportive care needsSystematic reviewModified Delphi consensus processPerson-centered careEnd of lifeData-driven careMultinational Association for Supportive CareDelphi consensus processSupportive careCancer survivorshipCare goalsIntegrated careCare experiencesCare needsCare frameworkHealth outcomesCommunicating careResourcing carePerson-centeredConsensus processSurvivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations
Hart N, Nekhlyudov L, Smith T, Yee J, Fitch M, Crawford G, Koczwara B, Ashbury F, Lustberg M, Mollica M, Smith A, Jefford M, Chino F, Zon R, Agar M, Chan R. Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations. Supportive Care In Cancer 2024, 32: 313. PMID: 38679639, PMCID: PMC11056340, DOI: 10.1007/s00520-024-08465-8.Peer-Reviewed Original ResearchConceptsQuality survivorship careSurvivorship carePractice recommendationsUnmet supportive care needsPalliative care frameworkSupportive care needsSystematic reviewModified Delphi consensus processEnd-of-lifeResultsA systematic reviewDelphi consensus processMethodsAn expert panelCancer survivorshipCare goalsCancer careCare experiencesCare needsCare frameworkHealth outcomesASCO membersConsensus processCareDelphi studyExpert panelMetastatic cancerA retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter?
McNally G, Aossey C, Wiczer T, Sinnott L, Lustberg M, Baiocchi R, Lustberg M. A retrospective cohort study describing chemotherapy-induced peripheral neuropathy in Non-Hodgkin lymphoma patients treated with EPOCH ± R: does HIV status matter? Leukemia & Lymphoma 2024, 65: 1110-1116. PMID: 38648546, DOI: 10.1080/10428194.2024.2340051.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyIncidence of chemotherapy-induced peripheral neuropathyHIV statusPeripheral neuropathyHIV-associated non-Hodgkin's lymphomaCohort studyDose-adjusted EPOCHNon-Hodgkin's lymphomaLong-term patient outcomesRetrospective cohort studyNon-HodgkinComprehensive cancer centerCancer CenterHIVPatientsNeuropathyPatient outcomesPropensity scoreLymphomaAdverse effectsIncidenceStatusRegimenVincristineLong-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopauseEyebrow and Eyelash Loss in Patients With Cancer.
Rose L, Khuhro A, Minta A, Novice M, Novice T, Lustberg M, Ruddy K, Rake E, Loprinzi C, Dulmage B. Eyebrow and Eyelash Loss in Patients With Cancer. Journal Of Drugs In Dermatology 2024, 23: 327-331. PMID: 38709698, DOI: 10.36849/jdd.8003.Peer-Reviewed Original ResearchConceptsPrevention optionsRadiation therapyTopical vasoconstrictorEndocrine therapyEyelash lossTreatment optionsPrescription medicationsCancer treatmentPatientsScalp coolingHair lossRobust researchMadarosisPermanent tattoosTherapyCancerTreatmentEyebrowsEyelash hairScalpOptionsChemotherapyCryotherapyVasoconstrictorDermatologistsThe Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatment